Japan Active Pharmaceutical Ingredient Cdmo Market Size & Outlook

The active pharmaceutical ingredient cdmo market in Japan is expected to reach a projected revenue of US$ 17,029.2 million by 2030. A compound annual growth rate of 7.8% is expected of Japan active pharmaceutical ingredient cdmo market from 2024 to 2030.
Revenue, 2023 (US$M)
$10,075.0
Forecast, 2030 (US$M)
$17,029.2
CAGR, 2024 - 2030
7.8%
Report Coverage
Japan

Japan active pharmaceutical ingredient cdmo market, 2018-2030 (US$M)

Japan

Related Markets

Japan active pharmaceutical ingredient cdmo market highlights

  • The Japan active pharmaceutical ingredient cdmo market generated a revenue of USD 10,075.0 million in 2023 and is expected to reach USD 17,029.2 million by 2030.
  • The Japan market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
  • In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2023.
  • Antibody Drug Conjugate (ADC is the most lucrative product segment registering the fastest growth during the forecast period.


Active pharmaceutical ingredient cdmo market data book summary

Market revenue in 2023USD 10,075.0 million
Market revenue in 2030USD 17,029.2 million
Growth rate7.8% (CAGR from 2023 to 2030)
Largest segmentTraditional active pharmaceutical ingredient (traditional api)
Fastest growing segmentAntibody Drug Conjugate (ADC
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationTraditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC
Key market players worldwideRecipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma


Other key industry trends

  • In terms of revenue, Japan accounted for 8.5% of the global active pharmaceutical ingredient cdmo market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China active pharmaceutical ingredient cdmo market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 25,242.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Active Pharmaceutical Ingredient CDMO Market Companies

Name Profile # Employees HQ Website

Japan active pharmaceutical ingredient cdmo market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.


Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.6% in 2023. Horizon Databook has segmented the Japan active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.


Some of the key drivers of Japan’s active pharmaceutical ingredients CDMO market are its growing pharmaceutical industry, rapid technological advancements, and high healthcare expenditure. Japan is expected to show lucrative growth rate of 9.6% during the forecast period.

Presence of a stringent regulatory framework and high standards for API manufacturing are increasing the overall costs, thus, promoting the need to maintain standards while reducing healthcare expenditure.

Furthermore, a large number of CDMO collaborations, expansions, mergers & acquisitions, and other strategic initiatives undertaken by market players operating in the country are anticipated to boost the market.

Reasons to subscribe to Japan active pharmaceutical ingredient cdmo market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan active pharmaceutical ingredient cdmo market databook

  • Our clientele includes a mix of active pharmaceutical ingredient cdmo market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Japan active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan active pharmaceutical ingredient cdmo market size, by product, 2018-2030 (US$M)

Japan Active Pharmaceutical Ingredient CDMO Market Outlook Share, 2023 & 2030 (US$M)

Japan active pharmaceutical ingredient cdmo market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more